











## **Prior Authorization Request Administrative Information**

Member Information							
Last name	First name		МІ				
Member ID	Date of birth						
Current gender    Female    Male    Transgender male    Transgender female    Other							
Place of residence							
Race/ethnicity Preferred spoken language Preferred written language							
MassHealth does not exclude people or treat them differently because of race, color, national origin, age, disability, religion, creed, sexual orientation, or sex (including gender identity and gender stereotyping).							
Plan Contact Information							
Please indicate the member's MassHealth Plan according to the Plan's contact information belo		his completed and signed	form				
MassHealth Fee-For-Service (FFS) Plan, Primary Care Clinician (PCC) Plan, Primary Care Accountable Care Organization (PCACO) Plan, Children's Medical Security Plan, and Health Safety Net Plan							
☐ MassHealth Drug Utilization Review Prog	gram						
Pharmacy: Fax: (877) 208-7428 - Tel: (800	) 745-7318						
MassHealth Managed Care Organization (MCO) and Accountable Care Partnership Plans (ACPP)							
☐ Fallon Health							
Online Prior Authorization: go.covermymeds.com/OptumRx							
Online Prior Authorization: providerportal.surescripts.net/ProviderPortal/optum							
Pharmacy: Fax: (844) 403-1029 - Tel: (844) 720-0033							
☐ Health New England							
Online Prior Authorization: go.covermymeds.com/OptumRx							
Pharmacy: Fax: (800) 550-9246 - Tel: (800) 918-7545							
Online Prior Authorization (Non-Specialty Drugs): go.covermymeds.com/OptumRx							
Online Prior Authorization (Specialty/Medical Drugs): provider.massgeneralbrighamhealthplan.org							
Pharmacy: Fax: (844) 403-1029 - Tel: (800) 711-4555							
☐ Tufts Health Plan							
Online Prior Authorization: point32health.promptpa.com							
Pharmacy: Fax: (617) 673-0939 - Tel: (888) 257-1985							
☐ WellSense Health Plan							
Online Prior Authorization: wellsense.org/providers/ma/pharmacy/prior-authorizations							
Pharmacy: Fax: (833) 951-1680 - Tel: (877) 417-1822							

## Anti-Obesity Agents Prior Authorization Request

MassHealth reviews requests for prior authorization (PA) on the basis of medical necessity only. If MassHealth approves the request, payment is still subject to all general conditions of MassHealth, including current member eligibility, other insurance, and program restrictions. MassHealth will notify the requesting provider and member of its decision. Keep a copy of this form for your records. If faxing this form, please use black ink.

Additional information about these agents, including PA requirements and preferred products, can be found within the MassHealth Drug List at www.mass.gov/druglist.

Medication information  Medication Requested  benzphetamine diethylpropion diethylpropion ER Lomaira (phentermine 8 mg tablet) orlistat	☐ phendimetrazine ER ☐ phentermine 15 mg, 30 mg capsule ☐ phentermine 37.5 mg capsule, tablet ☐ Saxenda (liraglutide) ☐ Wegovy (semaglutide injection)
phendimetrazine	Other Other
Dose and frequency of medication requested	
Is the member stabilized on the requested med	dication? Yes. Please provide start date.
Indication or ICD-10 code, if applicable  Obesity Overweight Other	
Section I. Please complete for all requests	
<ol> <li>Member's baseline weight</li> <li>Member's current weight</li> </ol>	Date
<ol> <li>Member's baseline BMI</li> <li>Will the member continue reduced-calorie diet</li> <li>Does the member have any of the following we Coronary heart disease or other atheroscle Dyslipidemia Hypertension Non-alcoholic steatohepatitis (NASH) Obstructive sleep apnea Systemic osteoarthritis Type 2 diabetes mellitus</li> </ol>	Date and increased physical activity?  Yes No eight-related comorbid conditions?
Other comorbidity	☐ Yes ☐ No
<ol> <li>For Saxenda and Wegovy requests, will the re receptor agonist? ☐ Yes ☐ No</li> </ol>	equested agent be used in combination with another GLP-1
7. For phentermine requests, will the requested a	agent be used in combination with topiramate?   Yes  No

PA-87 (Rev. 04/24) over

has the member had a trial with Saxenda or Wegovy?					
Yes. Please list the dates/duration of trials and outcomes below.					
Drug name					
	Othei				
· · · · · · · · · · · · · · · · · · ·					
No. Please describe why Saxenda and Wegovy are not appropriate for this member.					
tion II. Please complete for recertification requests.	_				
Name of a company of the Company of					
· · · · · · · · · · · · · · · · · · ·					
•					
Please provide clinical rationale for continuation of therapy.	_				
adverse reaction in, or physical or mental harm to the member?   Yes   No					
If ves. briefly describe details of contraindication, adverse reaction, or harm.					
If yes, briefly describe details of contraindication, adverse reaction, or harm.					
If yes, briefly describe details of contraindication, adverse reaction, or harm.					
Is the alternative drug required under the step therapy protocol expected to be ineffective based on the	nen?				
Is the alternative drug required under the step therapy protocol expected to be ineffective based on the known clinical characteristics of the member and the known characteristics of the alternative drug regime	nen?				
Is the alternative drug required under the step therapy protocol expected to be ineffective based on the known clinical characteristics of the member and the known characteristics of the alternative drug regim Yes No					
Is the alternative drug required under the step therapy protocol expected to be ineffective based on the known clinical characteristics of the member and the known characteristics of the alternative drug regime					
Is the alternative drug required under the step therapy protocol expected to be ineffective based on the known clinical characteristics of the member and the known characteristics of the alternative drug regim Yes No					
Is the alternative drug required under the step therapy protocol expected to be ineffective based on the known clinical characteristics of the member and the known characteristics of the alternative drug regim Yes No If yes, briefly describe details of known clinical characteristics of member and alternative drug regiment	า.				
Is the alternative drug required under the step therapy protocol expected to be ineffective based on the known clinical characteristics of the member and the known characteristics of the alternative drug regim Yes No If yes, briefly describe details of known clinical characteristics of member and alternative drug regiment.  Has the member previously tried the alternative drug required under the step therapy protocol, or another step therapy protocol.	า.				
Is the alternative drug required under the step therapy protocol expected to be ineffective based on the known clinical characteristics of the member and the known characteristics of the alternative drug regiment Yes No If yes, briefly describe details of known clinical characteristics of member and alternative drug regiment Has the member previously tried the alternative drug required under the step therapy protocol, or anoth alternative drug in the same pharmacologic class or with the same mechanism of action, and such	n. er				
Is the alternative drug required under the step therapy protocol expected to be ineffective based on the known clinical characteristics of the member and the known characteristics of the alternative drug regimentally of the protocol of the details of the member and the known characteristics of the alternative drug regimentally describe details of known clinical characteristics of member and alternative drug regimentally described the alternative drug required under the step therapy protocol, or anoth alternative drug in the same pharmacologic class or with the same mechanism of action, and such alternative drug was discontinued due to lack of efficacy or effectiveness, diminished effect, or an advertigation.	n. er				
Is the alternative drug required under the step therapy protocol expected to be ineffective based on the known clinical characteristics of the member and the known characteristics of the alternative drug regiment Yes No If yes, briefly describe details of known clinical characteristics of member and alternative drug regiment Has the member previously tried the alternative drug required under the step therapy protocol, or anoth alternative drug in the same pharmacologic class or with the same mechanism of action, and such	n. er				
Is the alternative drug required under the step therapy protocol expected to be ineffective based on the known clinical characteristics of the member and the known characteristics of the alternative drug regimently Yes. No  If yes, briefly describe details of known clinical characteristics of member and alternative drug regimently described the alternative drug required under the step therapy protocol, or anoth alternative drug in the same pharmacologic class or with the same mechanism of action, and such alternative drug was discontinued due to lack of efficacy or effectiveness, diminished effect, or an advert event?	n. er				
Is the alternative drug required under the step therapy protocol expected to be ineffective based on the known clinical characteristics of the member and the known characteristics of the alternative drug regimedry Yes No If yes, briefly describe details of known clinical characteristics of member and alternative drug regimedry.  Has the member previously tried the alternative drug required under the step therapy protocol, or anoth alternative drug in the same pharmacologic class or with the same mechanism of action, and such alternative drug was discontinued due to lack of efficacy or effectiveness, diminished effect, or an adverse event?  Yes No If yes, please provide details for the previous trial.	n. er				
Is the alternative drug required under the step therapy protocol expected to be ineffective based on the known clinical characteristics of the member and the known characteristics of the alternative drug regimently yes. No  If yes, briefly describe details of known clinical characteristics of member and alternative drug regimently.  Has the member previously tried the alternative drug required under the step therapy protocol, or anoth alternative drug in the same pharmacologic class or with the same mechanism of action, and such alternative drug was discontinued due to lack of efficacy or effectiveness, diminished effect, or an adverse event?  Yes No  If yes, please provide details for the previous trial.  Drug name  Dates/duration of use	n. er				
Is the alternative drug required under the step therapy protocol expected to be ineffective based on the known clinical characteristics of the member and the known characteristics of the alternative drug regimedry.  Yes No  If yes, briefly describe details of known clinical characteristics of member and alternative drug regimedry.  Has the member previously tried the alternative drug required under the step therapy protocol, or anoth alternative drug in the same pharmacologic class or with the same mechanism of action, and such alternative drug was discontinued due to lack of efficacy or effectiveness, diminished effect, or an adverse event?  Yes No  If yes, please provide details for the previous trial.  Drug name  Dates/duration of use  Did the member experience any of the following? Adverse reaction Inadequate response	n. er				
Is the alternative drug required under the step therapy protocol expected to be ineffective based on the known clinical characteristics of the member and the known characteristics of the alternative drug regimently yes. No  If yes, briefly describe details of known clinical characteristics of member and alternative drug regimently.  Has the member previously tried the alternative drug required under the step therapy protocol, or anoth alternative drug in the same pharmacologic class or with the same mechanism of action, and such alternative drug was discontinued due to lack of efficacy or effectiveness, diminished effect, or an adverse event?  Yes No  If yes, please provide details for the previous trial.  Drug name  Dates/duration of use	n. er				
1	tion II. Please complete for recertification requests.    Member's current weight				

4.	Is the member stable on the requested prescription drug prescribed by the health care provider, and switching drugs will likely cause an adverse reaction in or physical or mental harm to the member?					
	☐ Yes. Please provide details. ☐ No					
	Please continue to next page and complete Prescriber and Provider Information section.					

## **Prior Authorization Request Prescriber and Provider Information**

Prescriber Information		
Last name*	First name*	MI
NPI*	Individual MH Provide	er ID
DEA No.	Office Contact Name	
Address	City	State Zip
Email address		
Telephone No.*	Fax No.*	
* Required		
Please also complete for professionally	administered medication	ns, if applicable.
Start date	End date	
Servicing prescriber/facility name		☐ Same as prescribing provider
Servicing provider/facility address		
Servicing provider NPI/tax ID No.		
Name of billing provider		
Billing provider NPI No.		
Is this a request for recertification?  Yes	] No	
CPT code No. of visits	J code	No. of units
Prescribing provider's attestation, signal certify under the pains and penalties of perjoinformation section of this form. Any attached I certify that the medical necessity information complete, to the best of my knowledge. I under prosecution for any falsification, omission, or	ury that I am the prescribing I statement on my letterhead (per 130 CMR 450.204) on erstand that I may be subject concealment of any material	has been reviewed and signed by me. this form is true, accurate, and to civil penalties or criminal I fact contained herein.
Prescribing provider's signature		_
Printed name of prescribing provider  (The form can either be signed by hand and		

(The form can either be signed by hand and then scanned, or it can be signed electronically using DocuSign or Adobe Sign. For electronic signatures, the signer can upload a picture of their wet signature. The typed text of a signature is not an acceptable form of an electronic signature.)